Abstract
Interleukin 6 (IL-6) facilitates the differentiation of B cells to immunoglobulin-secreting cells and is reported to be a proliferative factor in some tumors. In this study, we examined IL-6 production in non-small cell lung carcinoma (NSCLC) and the proliferation of tumor cells following IL-6 treatment in vitro and in vivo. We analyzed the expression of IL-6 mRNA and protein in a series of 15 human lung cancer cell lines (four adenocarcinomas, five squamous cell carcinomas, two large cell carcinomas, and four small cell carcinomas) by reverse transcriptase polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA). We established an IL-6-producing cell line (ABC-1#IL-6) by transfecting a human IL-6 cDNA into a human non-IL-6-producing NSCLC cell line (ABC-1). These two cell lines were used to determine tumor cell proliferation both in vivo and in vitro in order to clarify the effect of IL-6 on tumor growth and metastasis. Athymic nude mice, SCID mice, and BALB/c mice were subcutaneously inoculated with these two cell lines, and body weight, tumor growth, and tumor doubling time were measured. The presence of IL-6 and tumor-infiltrating lymphocytes (TILs) within tumor tissues was examined by immunohistochemical staining. Results: Eight of 15 (53%) lung cancer cell lines expressed both IL-6 mRNA and protein. Tumor lesions of both cell lines developed in nude and SCID mice, although no such lesions of either cell lines developed in BALB/c mice. The tumor doubling time in nude and SCID mice was 2.97±1.22 days and 2.45±1.32 days, respectively, in mice inoculated with the cell line ABC-1#IL-6. These doubling times were statistically significantly shorter than those evident in mice inoculated with the control original ABC-1 cell line (nude, p=0.0337; SCID, p=0.0119; unpaired t-test). The rates of cell proliferation in vitro of the ABC-1#IL-6 and original ABC-1 cells lines were comparable (p=0.1441, unpaired t-test). Immunohistochemical staining revealed strong IL-6 expression in tumors derived from the IL-6-producing cell line but not in tumors derived from the original ABC-1 cell line (both in nude and SCID mice). Conclusion: 53% of lung cancer cell lines produce IL-6 mRNA and protein. Although IL-6 itself does not influence tumor cell proliferation in vitro, an association between IL-6 expression and tumor proliferation was found in vivo in nude and SCID mice. An anti-IL-6 reagent could provide a novel therapeutic strategy in patients with IL-6-producing lung tumors.
Similar content being viewed by others
References
Asselin-Paturel C, Echchakir H, Carayol G, Gay F, Opolon P, Grunenwald D, Chouaib S, Mami-Chouaib F (1998) Quantitative analysis of Th1, Th2 and TGF-beta1 cytokine expression in tumor, TIL and PBL of non-small cell lung cancer patients. Int J Cancer 77:7–12
Kataki A, Scheid P, Piet M, Marie B, Martinet N, Martinet Y, Vignaud J-M (2002) Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host- defence and tumor progression. J Lab Clin Med 140:320–328
Ortegel JW, Staren ED, Faber LP, Warren WH, Braun DP (2000) Cytokine biosynthesis by tumor-infiltrating T lymphocytes from human non-small-cell lung carcinoma. Cancer Immunol Immunother 48:627–634
Huang M, Wang J, Lee P, Sharma S, Mao Jenny T, Meissner H, Uyemura K, Modlin R, Wollman J, Dubinett SM (1995) Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res 55:3847–3853
Abbas AK, Murphy KM, Sher A (1996) Functional diversity of helper T lymphocytes. Nature 383:787–793
Kuninaka S, Yano T, Yokoyama H, Fukuyama Y, Terazaki Y, Uehara T, Kanematsu T, Asoh H, Ichinose Y (2000) Direct influences of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) on the proliferation and cell-surface anigen expression of cancer cells. Cytokine 12:8–11
Iizasa T, Fujisawa T, Suzuki M, Shin-ichirou M, Yasufuku K, Yasukawa T, Baba M, Shiba M (1999) Elevated levels of circulating plasma Matrix Metalloproteinase 9 in non-small cell lung cancer patients. Clin Cancer Res 149:149–153
Miller AD, Rosman GJ (1989) Improved retroviral vectors for gene transfer and expresion. Biotechniques 7:980–990
Mosmann TR, Moore KW (1991) The role of IL-10 in crossregulation of TH1 and TH2 responses. Immunol Today 12:49–53
Ortegel JW, Staren ED, Faber LP, Warren WH, Braun DP (2002) Modulation of tumor-Infiltrating lymphocyte cytolytic activity against human non-small cell lung cancer. Lung Cancer 36:17–25
Dosquet C, Schaetz A, Faucher C, Lepage E, Wautier JL, Richard F, Cabane J (1994) Tumour necrosis factor-alpha, interleukin-1beta and interleukin-6 in patients with renal cell carcinoma. Eur J Cancer 30(A):162–167
Eustace D, Han X, Gooding R, Rowbottom A, Riches P, Heyderman E (1993) Interleukin-6 (IL-6) function as an autocrine growth factor in cevical carcinomas in vitro. Gynecol Oncol 50:15–19
Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, Kuramoto A, Kishimoto T (1988) Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332:83–85
Mouawad R, Benhammouda A, Rixe O, Antonie E C, Borel C, Weil M, Khayat D, Soubrane C (1996) Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden. Clin Cancer Res 2:1405–1409
Miki S, Iwano M, Miki Y, Yamamoto M, Tang B, Yokokawa K, Sonoda T, Hirano T, Kishimoto T (1989) Interleukin-6 (IL-6) function as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett 250:607–610
Watson JM, Sensintaffer JL, Berek JS, Martinez-Maza O (1990) Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res 50:6959–6965
Wu S, Rodabaugh K, Martinez-Maza O, Watson JM, Silberstein DS, Boyer CM, Peters WP, Weinberg JB, Berek JS, Bast Robert C Jr (1992) Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor. Am J Obstet Gynecol 166:997–1007
Takizawa H, Ohtoshi T, Ohta K, Yamashita N, Hirohata S, Hirai K, Hiramatsu K, Ito K (1993) Growth inhibition of human lung cancer cell lines by interleukin 6 in vitro: a possible role in tumor growth via an autocrine mechanism. Cancer Res 53:4175–4181
Kishimoto T (1989) The biology of Interleukin-6. Blood 74:1–10
Saito K, Ishikura H, Kishimoto T, Kawarada Y, Yano T, Takahashi T, Hiroyuki K, Yoshiki T (1998) Interleukin-6 produced by pancreatic carcinoma cells enhances humoral immune responces against tumor cells: a possible event in tumor regression. Int J Cancer 75:284–289
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yamaji, H., Iizasa, T., Koh, E. et al. Correlation between interleukin 6 production and tumor proliferation in non-small cell lung cancer. Cancer Immunol Immunother 53, 786–792 (2004). https://doi.org/10.1007/s00262-004-0533-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-004-0533-9